Antibe Therapeutics Inc.
ATE
Classificação em ações
#31903
Antibe Therapeutics Inc. is a biotechnology company specializing in the... Antibe Therapeutics Inc. is a biotechnology company specializing in the development of groundbreaking therapeutics and medical devices. Operating internationally, including Canada, Europe, and the United States, their work targets pain, inflammation, and regenerative medicine. A key focus is developing drugs designed to prevent the gastrointestinal harm and bleeding often caused by non-steroidal anti-inflammatory drugs. Their leading candidate, Otenaproxesul, is a hydrogen sulfide-releasing derivative of naproxen. This compound has already finished a Phase 2B gastrointestinal safety study and is being investigated for a range of indications, such as post-operative pain, migraines, dysmenorrhea, traumatic injuries, dental pain, and gout. Additionally, their product portfolio features ATB-352, currently in preclinical development for managing acute pain. The company, incorporated in 2009, is headquartered in Toronto, Canada.
Preço da ação
$0.21483059
Última sincronização: 2024-05-07
Valor de mercado
$11.13M
Variação (1 dia)
0.34%
Variação (1 ano)
-0.36%
País
CA
Negociar Antibe Therapeutics Inc. (ATE)
Categoria
Healthcare
Histórico de rendimento de dividendos para Antibe Therapeutics Inc. (ATE)
O rendimento de dividendos (TTM) da Antibe Therapeutics Inc. (símbolo da ação: ATE) em 2026 é: 0
Rendimento médio dos dividendos nos últimos 5 anos: 0.00%
Rendimento médio dos dividendos nos últimos 5 anos: 0.00%
Histórico de rendimento de dividendos para Antibe Therapeutics Inc. (ATE) de 2026 a 2026
Rendimento de dividendos no final de cada ano (TTM)
| Ano | Rendimento de Dividendos | Alterar |
|---|---|---|
| Não há dados suficientes para as datas fornecidas. | ||
Rendimentos de dividendos (TTM) para empresas semelhantes ou concorrentes
| Empresa | Rendimento de Dividendos | País |
|---|---|---|
| 2.45% |
US
|
|
| 3.69% |
IE
|
|
| 1.25% |
US
|
|
| 0.00% |
US
|
|
| 0.00% |
DE
|
